OSARO Inc., a rising leader in machine learning software for industrial automation, and INNOTECH Corp. (HQ: Kohoku Ward, Yokohama City, Representative: Toshihiko Ono) have announced a collaboration to establish the Innotech AI Picking Lab in Yokohama City to support Japanese customers in various industries through improved warehouse and distribution operations.
Through this new collaboration, INNOTECH will develop and popularize general purpose and highly expandable pick-and-place automation products and solutions that will integrate their robots and peripherals with OSARO AI software. In particular, INNOTECH will expand activities for both logistics and factory automation, while the strength of OSARO’s AI software will allow INNOTECH to expand automation activities, targeting the food, medicine, and cosmetics industries.
INNOTECH has extensive experience conducting license sales activities. In cooperation with OSARO, the new venture will expand their customer outreach, providing AI model creation and technical support, as the companies explore new products and solutions for automation.
We are very pleased to open this speciality lab with OSARO, expanding our relationship to serve our customers needs. We strive to be a solution provider that, together with OSARO, proposes a wide range of technologies and services that meet the needs of our customers, stated Yosuke Kaburagi, Director of INNOTECH Corp., at the opening of the lab.
On behalf of the entire OSARO team, I would like to thank INNOTECH for their collaboration in creating the Innotech AI Picking Lab. We look forward to continuing our work with INNOTECH as the lab uses OSARO robotics automation software to develop new products and solutions for industrial automation, said Derik Pridmore, CEO of OSARO.
ABOUT INNOTECH CORPORATION
INNOTECH is a Japan-based company providing comprehensive technology and support solutions for customer product development and manufacturing. Since 2000, INNOTECH has engaged in the business of internally developed products, leveraging its technical knowledge, strengthened by its existing and expanding business relationships. Today, INNOTECH continues to evolve as a total solution company, with hardware, software, consulting and support offerings for customers design, development, and mass production activities, leading up to the introduction of their final products.
OSARO is a machine learning company with offices in San Francisco and Tokyo, specializing in AI software for industrial automation. OSARO software gives robots new levels of sight and skill to enable practical productivity solutions for the factories and logistics systems of the 21st century. OSARO is a pioneer of a unique “software only” approach for AI in the industrial automation space. In a post-COVID world, OSARO AI software for warehouse automation makes the global supply chain smarter by helping e-commerce scale safely and reliably. OSARO began deploying its first solution in Japan in early 2018. To date, OSARO has raised $29.3 million from prominent venture capital firms and strategic investors to increase its talent pool, international deployments, and to advance the OSARO product lines to meet customer demands.
For more information, visit www.osaro.com and follow the company @osaroAI.
To access Press Kit: https://drive.google.com/drive/u/0/folders/1T-DtACP37zKnStJj6-_lgu2NHyhAMWEk
Tracy Nguyen, [email protected]
IT Tech Packaging, Inc. Advances Additional Orders Negotiation with One of Its Top 5 Customers
BAODING, China, Sept. 24, 2020 /PRNewswire/ — IT Tech Packaging, Inc. (NYSE American: ITP) ("IT Tech Packaging" or "the Company"), a leading manufacturer and distributor of diversified paper products in North China, today announced that the Company is advancing negotiation with one of its top 5 customers, based in Shandong Province for orders of the paper products. The customer is currently ranked among the top 5 customers of the Company during the past couple of years.
Based on the negotiation, the Company and the customer will further cooperate on products supply and purchase in the next quarters and definitive new contracts are expected to be signed by the end of the year. Based on its increasing clients’ demand, the customer will continue to increase its purchase orders from the Company.
Mr. Zhenyong Liu, Chairman and Chief Executive Officer of IT Tech Packaging commented, "We are pleased with the negotiation with the customer for further partnership. As Chinese economy recovers from the COVID-19 epidemic with an amazing pace, our top clients such as companies focusing on printing and packaging are also receiving amount of orders and some even have backlog of orders, so they push forward the negotiations for raw materials and increase purchase volume of our products. We appreciate their confidence in our products as well as efficiency of delivery. We hope the stable partnership between us will continue contributing considerable revenue stream in the upcoming quarters."
About IT Tech Packaging, Inc.
Founded in 1996, IT Tech Packaging, Inc. is a leading manufacturer and distributor of diversified paper products in North China. Using recycled paper as its primary raw material (with the exception of its tissue paper products), ITP produces and distributes three categories of paper products: corrugating medium paper, offset printing paper and tissue paper products. With production based in Baoding and Xingtai in North China’s Hebei Province, ITP is located strategically close to the Beijing and Tianjin region, home to a growing base of industrial and manufacturing activities and one of the largest markets for paper products consumption in the country. ITP has been listed on the NYSE American since December 2009.
Safe Harbor Statements
This press release may contain forward-looking statements. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks outlined in the Company’s public filings with the Securities and Exchange Commission, including the Company’s latest annual report on Form 10-K. All information provided in this press release speaks as of the date hereof. Except as otherwise required by law, the Company undertakes no obligation to update or revise its forward-looking statements.
For more information, please contact:
At the Company Email:
Tel: +86 0312 8698215
EverGreen Consulting Inc.
Email: [email protected]
Related Links :
Helios Technologies Declares 96th Sequential Quarterly Cash Dividend
Helios Technologies (Nasdaq: HLIO) (Helios or the Company), a global industrial technology leader that develops and manufactures solutions for both the hydraulics and electronics markets, announced that its Board of Directors declared a quarterly cash dividend of $0.09 per common share. Helios Technologies has declared ninety-six consecutive quarterly dividends to its stockholders beginning with the first quarter 1997.
We are pleased that the continued success of our operations has allowed us to be a consistent dividend payer over the last twenty-four years, commented Josef Matosevic, the Companys President and Chief Executive Officer.
The dividend will be payable on October 20, 2020 to stockholders of record as of October 5, 2020. Helios Technologies has approximately 32.1 million shares of common stock outstanding.
About Helios Technologies
Helios Technologies is a global industrial technology leader that develops and manufactures hydraulic and electronic control solutions for diverse markets. The Company operates in two business segments, Hydraulics and Electronics. The Hydraulics segment markets and sells products globally under the brands of Sun Hydraulics in relation to cartridge valve technology, Custom Fluidpower with regard to hydraulic system design and Faster in connection with quick release coupling solutions. Global Electronics brands include Enovation Controls and Murphy for fully-tailored solutions with a broad range of rugged and reliable instruments such as displays, controls and instrumentation products. Helios Technologies and information about its associated companies is available online at www.heliostechnologies.com.
Anokion Announces FDA Clearance of IND Application for ANK-700 for the Treatment of Multiple Sclerosis
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ANK-700, an antigen-specific drug candidate for the treatment of multiple sclerosis (MS). Anokion plans to initiate a multi-center, Phase 1 clinical trial of ANK-700 in people with MS by the end of this year.
Multiple sclerosis remains a devastating disease that significantly impacts those who suffer from it, including family members and caregivers. Unfortunately, available interventions offer limited benefit and often do not address the underlying mechanisms that advance disease, said Simon Cooper, M.B.B.S., chief medical officer of Anokion. By harnessing the natural immune tolerance pathways in the liver, ANK-700 aims to re-educate the immune system with a potentially transformative approach that induces antigen-specific tolerance to CNS autoantigens and treats neuroinflammation. This IND marks the second clinical-stage program in our pipeline, and we look forward to initiating enrollment in the Phase 1 trial with ANK-700 later this year.
In preclinical models, Anokion has demonstrated that the tolerogenic T cell mechanisms induced by its potent, liver-targeting technology were effective at preventing or reducing disease pathology for MS. In a mouse model of MS, a liver-targeting myelin oligodendrocyte glycoprotein (MOG) antigen induced pathogenic T cell anergy and deletion, resulting in protection from disease onset and therapeutic remission when tolerized during active disease. These preclinical data were consistent with functional and mechanistic findings in a non-human primate model, supporting the translational potential in treating MS with ANK-700.
About Anokion Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokions distinct approach leverages the companys immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease. For more information, please visit http://www.anokion.com/.
THRUST Strategic Communications
IT Tech Packaging, Inc. Advances Additional Orders Negotiation with One of Its Top 5 Customers
BAODING, China, Sept. 24, 2020 /PRNewswire/ — IT Tech Packaging, Inc. (NYSE American: ITP) ("IT Tech Packaging" or "the Company"),...
Glucuronolactone Market Procurement Intelligence Report With COVID-19 Impact Analysis | Global Forecasts, 2020-2024 | SpendEdge
The Glucuronolactone market will register an incremental spend of about $86 million, growing at a CAGR of 4.53% during the...
Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia to Advance Type 1 and Type 2 Diabetes Research
DexCom, Inc. (NASDAQ:DXCM) today announced it has signed a five-year collaboration agreement with the University of Virginia to advance its...
Solomon D. Trujillo Appointed to Chairman of Encantos
Encantos, the award-winning entertainment-driven edtech company creating direct-to-learner family brands, announced today that Solomon (Sol) Trujillo has been appointed as...
Phunware Announces Upward Revision to Third Quarter Net Revenues Guidance
Phunware, Inc. (NASDAQ: PHUN) (the Company), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services...
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant...
Canadian Municipalities Join Forces With Operation Lifesaver to Raise Awareness About Rail-Crossing Safety
Every year, dozens of Canadians are killed or seriously injured in collisions at railway crossings. In fact, there were 174...
Jitsi and Mattermost Team Up for Joint Hackathon – “Thriving in a Remote Environment”
8×8, Inc. (NYSE: EGHT), a leading integrated cloud communications platform, today announced a joint hackathon hosted by Jitsi and Mattermost...
OSI Systems Receives $59 Million Contract to Provide Security Inspection Systems to Hamad International Airport
OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced that its Security division was awarded a contract...
IDC Launches the Future of Industry Ecosystems: Built on the Platform and Sharing Economy
The tactical and strategic priority list for leadership, built on the premise of a steady rate of change, has changed...